Search

Your search keyword '"Hanefeld, Markolf"' showing total 639 results
Start Over Author "Hanefeld, Markolf"
639 results on '"Hanefeld, Markolf"'

2. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial

Author

Bajaj, Harpreet S, Gerstein, Hertzel C, Rao-Melacini, Purnima, Basile, Jan, Colhoun, Helen, Conget, Ignacio, Cushman, William C, Dagenais, Gilles R, Franek, Edward, Hanefeld, Markolf, Keltai, Matyas, Lakshmanan, Mark, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Pirags, Valdis, Pogosova, Nana, Probstfield, Jeffrey, Raubenheimer, Peter, Ryden, Lars, Shaw, Jonathan E, Sheu, Wayne H-H, and Xavier, Denis

Published
2021
Full Text
View/download PDF

3. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Author

Gerstein, Hertzel C, Hart, Robert, Colhoun, Helen M, Diaz, Rafael, Lakshmanan, Mark, Botros, Fady T, Probstfield, Jeffrey, Riddle, Matthew C, Rydén, Lars, Atisso, Charles Messan, Dyal, Leanne, Hall, Stephanie, Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C, Hancu, Nicolae, Hanefeld, Markolf, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Muñoz, Ernesto Germán Cardona, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, and Temelkova-Kurktschiev, Theodora

Published
2020
Full Text
View/download PDF

13. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

Author

Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Atisso, Charles M., Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez‐Jaramillo, Patricio, Cardona‐Munoz, Ernesto G., Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan, Sheu, Wayne H‐H., and Temelkova‐Kurktschiev, Theodora

Published
2018
Full Text
View/download PDF

32. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias

Author

Stahn, Annett, Pistrosch, Frank, Ganz, Xenia, Teige, Madlen, Koehler, Carsta, Bornstein, Stefan, and Hanefeld, Markolf

Subjects
Cholesterol, Diabetes therapy, Dextrose, Electrocardiography, Glucose, Cardiovascular diseases -- Care and treatment, Glucose metabolism, Electrocardiogram, Type 2 diabetes -- Care and treatment, Health
Abstract

OBJECTIVE In patients with type 2 diabetes and cardiovascular diseases (CVDs), intensive treatment with insulin and/or sulfonylurea (SU) may be associated with excessive increased risk of hypoglycemic episodes. To evaluate [...]

Published
2014
Full Text
View/download PDF

37. An exploratory analysis of the REWIND trial

Author

Gerstein, Hertzel C., Hart, Robert, Colhoun, Helen M., Diaz, Rafael, Lakshmanan, Mark, Botros, Fady T., Probstfield, Jeffrey, Riddle, Matthew C., Rydén, Lars, Messan Atisso, Charles, Dyal, Leanne, Hall, Stephanie, Avezum, Alvaro, Basile, Jan, Conget, Ignacio, Cushman, William C., Hancu, Nicolae, Hanefeld, Markolf, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez-Jaramillo, Patricio, Cardona Muñoz, Ernesto Germán, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan E., Sheu, Wayne H-H., Temelkova-Kurktschiev, Theodora, and Everest

Abstract

Digital, Background Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial. Methods REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c was 9·5% or less (with no lower limit) on stable doses of up to two oral glucose-lowering drugs with or without basal insulin therapy were eligible if their body-mass index was at least 23 kg/m2. Participants were randomly assigned (1:1) to weekly subcutaneous injections of either masked dulaglutide 1·5 mg or the same volume of masked placebo (containing the same excipients but without dulaglutide). Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked. During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week. Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined. Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until 1200 confirmed primary outcomes accrued. The primary endpoint was the first occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes. All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials.gov, number NCT01394952. Findings Between Aug 18, 2011, and Aug 14, 2013, we screened 12 133 patients, of whom 9901 with type 2 diabetes and additional cardiovascular risk factors were randomly assigned to either dulaglutide (n=4949) or an equal volume of placebo (n=4952). During a median follow-up of 5·4 years, cerebrovascular and other cardiovascular outcomes were ascertained and adjudicated. 158 (3·2%) of 4949 participants assigned to dulaglutide and 205 (4·1%) of 4952 participants assigned to placebo had a stroke during follow-up (hazard ratio [HR] 0·76, 95% CI 0·62–0·94; p=0·010). Dulaglutide reduced ischaemic stroke (0·75, 0·59–0·94, p=0·012) but had no effect on haemorrhagic stroke (1·05, 0·55–1·99; p=0·89). Dulaglutide also reduced the composite of non-fatal stroke or all-cause death (0·88, 0·79–0·98; p=0·017) and disabling stroke (0·74, 0·56–0·99; p=0·042). The degree of disability after stroke did not differ by treatment group. Interpretation Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity., Ciencias Médicas y de la Salud

Published
2020

39. Rosiglitazone evaluated for cardio-vascular outcomes - An interim analysis

Author

Home, Phillip D., Pocock, Stuart J., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Jones, Nigel P., Komajda, Michel, and McMurray, John J.V.

Subjects
Type 2 diabetes -- Drug therapy, Rosiglitazone maleate -- Dosage and administration, Rosiglitazone maleate -- Complications and side effects, Cardiovascular diseases -- Risk factors
Abstract

The treatment of type 2 diabetes with Rosiglitazone and its resulting long-term effect on cardio-vascular system is outlined.

Published
2007

43. Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)

Author

Lonn, Eva M., Bosch, Jackie, Diaz, Rafael, Lopez-Jaramillo, Patricio, Ramachandran, Ambady, Hâncu, Nicolae, Hanefeld, Markolf, Krum, Henry, Ryden, Lars, Smith, Sandra, McQueen, Matthew J., Dyal, Leanne, Yusuf, Salim, and Gerstein, Hertzel C.

Published
2013
Full Text
View/download PDF

46. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

Author

Chiasson, Jean-Louis, Josse, Robert G., Gomis, Ramon, Hanefeld, Markolf, Karasik, Avraham, and Laakso, Markku

Subjects
Glucose intolerance -- Drug therapy, Acarbose -- Evaluation, Heart attack -- Prevention, Hypertension -- Prevention, Cookery for hypertensives -- Prevention
Abstract

Treating people with impaired glucose tolerance with acarbose may reduce their risk of developing high blood pressure and cardiovascular disease, according to a study of 1,368 patients. The most significant benefit was a 90% lower rate of heart attacks in the patients who took acarbose. Impaired glucose tolerance is considered an early sign of type 2 diabetes.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results